Reduced myocardial perfusion is common among subjects with ischemia and no obstructive coronary artery disease and heart failure with preserved ejection fraction: a report from the WISE-CVD continuation study

Haider Aldiwani1, Michael D. Nelson1,2, Behzad Sharif1, Janet Wei1, T. Jake Samuel2, Nissi Suppogu1, Odayme Quesada2, Galen Cook-Wiens1, Edward Gill2, Lidia S. Szczepaniak1, Louise E. J. Thomson1, Balaji Tamarappoo1, Anum Asif1, Chrisandra Shufelt1, Daniel Berman1, C. Noel Bairey Merz1

1Barbra Streisand Women’s Heart Center, Cedars-Sinai Smidt Heart Institute, Los Angeles, CA 90048, USA.
2Applied Physiology and Advanced Imaging Laboratory, University of Texas, Arlington, TX 76019, USA.

Abstract

Aim: Women with evidence of ischemia and no obstructive coronary artery disease (INOCA) have an increased risk of major adverse cardiac events, including heart failure with preserved ejection fraction (HFpEF). To investigate potential links between INOCA and HFpEF, we examined pathophysiological findings present in both INOCA and HFpEF.

Methods: We performed adenosine stress cardiac magnetic resonance imaging (CMRI) in 56 participants, including 35 women with suspected INOCA, 13 women with HFpEF, and 8 reference control women. Myocardial perfusion imaging was performed at rest and with vasodilator stress with intravenous adenosine. Myocardial perfusion reserve index was quantified as the ratio of the upslope of increase in myocardial contrast at stress vs. rest. All CMRI measures were quantified using CVI42 software (Circle Cardiovascular Imaging Inc). Statistical analysis was performed using linear regression models, Fisher’s exact tests, ANOVA, or Kruskal-Wallis tests.

This article is licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Correspondence to: C. Noel Bairey Merz, MD, Barbra Streisand Women’s Heart Center, Cedars-Sinai Smidt Heart Institute, San Vicente Blvd, Suite A3600, Los Angeles, CA 9004, USA. Noel.BaireyMerz@cshs.org.

Authors’ contributions
Writing original draft, formal analysis, data curation, visualization: Aldiwani H Conceptualization, funding acquisition, writing, review and editing, supervision: Merz CNB Writing, review and editing, investigation, and validation: Nelson MD, Sharif B, Wei J, Samuel TG, Suppogu N, Quesada O, Cook-Wiens G, Gill E, Szczepaniak LS, Thomson LEJ, Tamarappoo B, Asif A, Shufelt C, Berman D

DECLARATIONS
Ethical approval and consent to participate
Not applicable.
Consent for publication
Not applicable.
**Results:** Age ($P = 0.007$), Body surface area ($0.05$) were higher in the HFpEF group. Left ventricular ejection fraction ($P = 0.02$) was lower among the INOCA and HFpEF groups than reference controls after age adjustment. In addition, there was a graded reduction in myocardial perfusion reserve index in HFpEF vs. INOCA vs. reference controls ($1.5 \pm 0.3, 1.8 \pm 0.3, 1.9 \pm 0.3, P = 0.02$), which was attenuated with age-adjustment.

**Conclusion:** Reduced myocardial perfusion reserve appears to be a common pathophysiologic feature in INOCA and HFpEF patients.

**Keywords**

Non-obstructive coronary artery disease; cardiac magnetic resonance imaging; coronary microvascular dysfunction; heart failure with preserved ejection fraction

---

**INTRODUCTION**

Women with evidence of ischemia and no obstructive coronary artery disease (INOCA) are at increased risk of developing major adverse cardiovascular events, most commonly heart failure with preserved ejection fraction (HFpEF)[1–3]. Up to 50% of women with INOCA have coronary microvascular dysfunction (CMD) with impaired myocardial perfusion reserve, most often detected by reduced coronary flow reserve through invasive coronary function testing (CFT) or non-invasive imaging such as cardiac magnetic resonance imaging (CMRI) or positron emission tomography[4,5]. Previous studies demonstrated that women with CMD often have left ventricular (LV) diastolic dysfunction, adverse ventricular remodeling, elevated inflammatory markers, and myocardial scar[6–8]. However, the mechanism(s) linking HFpEF with INOCA remains to be elucidated. Accordingly, we hypothesized that CMD might be contributing to adverse ventricular remodeling in INOCA and subsequently to HFpEF. We tested our hypothesis by evaluating LV remodeling and myocardial perfusion abnormalities in participants with CMD, HFpEF, and reference controls.

**METHODS**

Sixty-four participants were recruited, including 36 women with suspected INOCA, 20 with HFpEF (14 women and 6 men), and 8 reference control women. All study participants selection criteria and intervention are illustrated in Figure 1. Participants in the INOCA and the HFpEF groups were recruited from the Women’s Ischemia Syndrome Evaluation - Coronary Vascular Dysfunction (WISE-CVD) Continuation Study, also known as Women’s Ischemia Syndrome Evaluation - CMD and HFpEF at Cedars-Sinai Medical Center, Los Angeles, CA NCT02582021. All women with INOCA underwent clinically indicated invasive CFT after demonstration of no obstructive coronary artery disease (CAD), defined as < 50% stenosis. CFT is considered the gold standard invasive test to diagnose CMD and published previously[9]. In brief, CFT was performed by infusing vasoactive substances through a guiding catheter placed in the left main coronary artery. The Doppler guide wire was positioned in the proximal left anterior descending coronary artery, and test results are interpreted in Table 1[9].
All participants hospitalized for HFpEF were enrolled. All participants met modified criteria for diagnosis of HFpEF based on the European Society of Cardiology guidelines (2012) [10], including symptoms of heart failure (e.g., dyspnea, orthopnea, paroxysmal nocturnal dyspnea, and edema), left ventricular ejection fraction $> 45\%$ prior to study entry, structural evidence of cardiovascular abnormalities: evidence of abnormal filling or relaxation, left atrial enlargement or left ventricular hypertrophy documented by echocardiogram and evidence of elevated filling pressure pressures: left ventricular end-diastolic pressure or pulmonary capillary wedge pressure at rest $>15$ mmHg, elevated brain natriuretic peptide, or use of diuretics. In addition, participants who had the following were excluded: LVEF $< 45\%$, Acute coronary syndrome (defined by ACC/AHA guidelines, including MI within 3 months of entry, patients who have had an MI or other event within the 6 months prior to entry unless an echocardiogram measurement performed after the event confirms a LVEF $\geq 45\%$, primary valvular heart disease ($> \text{moderate regurgitation or } > \text{mild stenosis}$), primary cardiomyopathies (hypertrophic, infiltrative or restrictive), constrictive pericarditis, high-output heart failure and right ventricular myopathies, patients with concurrent cardiogenic shock or requiring inotropic or intra-aortic balloon support or current acute decompensated HF requiring therapy, alternative reason for dyspnea such as: significant pulmonary disease or severe COPD, hemoglobin less than 10 g/dL or body mass index more than 40 kg/m$^2$, systolic blood pressure (SBP) $\geq 180$ mmHg at entry, or SBP $> 150$ mmHg and $< 180$ mmHg at entry unless the patient is receiving 3 or more antihypertensive drugs, prior or planned percutaneous coronary intervention or coronary artery bypass grafting, Non-cardiac illness with a life expectancy less than 4 years, inability to give informed consent, contraindication to CMRI, end stage renal disease, end stage liver disease. In addition, obstructive CAD was excluded by noninvasive coronary computed tomography angiography in this group due to the lack of clinically indicated CFT. Reference control women were recruited from the Cardiac Magnetic Resonance Imaging Normal Reference Control Group Testing study NCT00573339.

Women had no symptoms suggestive of cardiovascular ischemia and cardiovascular risk factors and had a non-ischemic Bruce protocol exercise treadmill stress test. The study was approved by the institutional review board, and all participants provided written informed consent.

For stress, all participants received either adenosine ($n = 59$) (140 μg/kg for 3 min) or regadenoson ($n = 5$) stress-rest perfusion (0.4 mg). CMRI was per) and a standardized gadolinium bolus of 0.05 mmol/kg injected at 4 mformed using standardized product sequences (3T Siemens Healthcare, Erlangen, GermanyL/s (Gadavist gadobutrol injection 1 mmol/mL) during stress and rest. First-pass perfusion images were obtained in three LV short-axis slices (basal, mid, and distal LV slice positions) with the following parameters: Gradient echo - EPI hybrid sequence, TR per slice 134.8 ms, TE 0.94 ms, BW 1240 Hz/pixel, readout flip angle 43°, slice thickness 8 mm, image matrix 155 × 224 pixels, in-plane resolution 1.34 mm $\times$ 1.34 mm $\times$ 8 mm$^2$, parallel imaging (GRAPPA) factor 2, imaging three slices every heartbeat. In the event of a peak stress heart rate of $> 120$ bpm, two slices were obtained during stress first-pass imaging with the exclusion of the distal LV slice position. Cardiac morphology and function were assessed using a stack of short-axis cine images spanning the entire LV, together with a series of long-axis images in the horizontal,
vertical, and LV outflow tract views. Typical scan parameters included contiguous 8 mm/0 mm slices, 1.34 mm × 1.34 mm × 8 mm voxel size, 155 mm × 224 mm matrix, 25 cardiac phases, 11 segments, 10 heartbeats/slice. Visual assessment of splenic switch-off for evaluation of stress test adequacy was performed in participants who received adenosine.

All CMRI data were quantified and analyzed using CVI42 software (Circle Cardiovascular Imaging Inc.). Myocardial perfusion reserve index (MPRI) was calculated as previously published[5]. The Seattle Angina Questionnaire (SAQ), measuring five functional dimensions, was used to characterize clinical symptoms (higher scores indicate less angina). Kansas City Cardiomyopathy Questionnaire (KCCQ) was used to characterize heart failure symptoms (higher scores indicate better HF symptoms). Left ventricular mass and end-systolic and end-diastolic volumes were indexed to the body surface area.

We analyzed a total of 56 women participants and excluded men participants and participants with an EF of less than 50%, as shown in Figure 2 according to the most recent ESC guidelines to diagnose HFpEF[11].

Statistical analysis

Age-adjusted p-values were statistically obtained using linear regression models, and non-adjusted P-values were obtained using either Fisher’s exact tests, ANOVA, or Kruskal-Wallis tests using SAS software.

RESULTS

Pertinent baseline characteristics are summarized in Table 1. Age and body surface area (BSA) differed among the groups; participants with HFpEF were the oldest and had the highest BSA compared to women with INOCA and reference controls. Participants with INOCA and HFpEF shared different percentages of common cardiovascular risk factors, including hypertension, diabetes mellitus (DM), dyslipidemia, former smoking history, and family history of premature CAD. Essential hypertension and DM were prevalent among the HFpEF group compared to the INOCA group (75%, 40%, P = 0.003, 30.8%, 6.5%, P = 0.05) while family history of CAD was prevalent among the INOCA group compared to the HFpEF group (71%, 46.2%, P = 0.04). Both groups had similar use of calcium channel blockers, aspirin, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and statins. The β-blocker use was more prevalent in the HFpEF group than in the INOCA (80%, 22.2%, P = 0.002). As expected, the INOCA group had lower SAQ scores compared to the HFpEF group, indicating relatively severe angina symptoms. Interestingly, KCCQ symptoms were modestly reduced among the INOCA and the HFpEF groups, and there were no statistically significant differences between them across all the domains.

CMRI results are shown in Table 1. LV ejection fraction differed across the groups after adjusting for age and demonstrating a significant decrease among HFpEF and INOCA groups compared to reference controls. LV volumes, LV mass, LV mass to volume ratio were not statistically different across the groups. Consistent with our hypothesis, we observed a graded reduction in subendocardial, subepicardial, and transmural MPRI among HFpEF, INOCA, and reference controls. These findings were attenuated by age adjustment;
however, epicardial MPRI remained statistically significant across the groups. Results for the CFT among the INOCA population are illustrated in Table 1.

DISCUSSION

The data supports the hypothesis that reduced myocardial perfusion is a common pathophysiologic feature in INOCA and HFpEF patients. These data show a reduction in LVEF and impaired myocardial perfusion reserve in patients with suspected INOCA and patients with HFpEF. The perfusion abnormality was worse among participants with HFpEF than INOCA and raised the question of whether INOCA and HFpEF share similar pathophysiological processes but worse in HFpEF than INOCA. Although myocardial perfusion was reduced in both INOCA and HFpEF, only the epicardial MPRI remained statistically significantly different following age adjustment. Similar to women with HFpEF, women with INOCA showed significant symptoms related to HF evidenced by the KCCQ assessment.

Women with suspected INOCA are at increased risk of developing major adverse cardiovascular events, most commonly HFpEF\[^1\text{–}^3\]; however, the contributing mechanism(s) to subsequent heart failure progression in INOCA has not been well characterized. Recent results from the PROMIS-HFpEF trial showed a high prevalence of CMD evident from reduced coronary flow reserve measured using adenosine stress transthoracic Doppler echocardiography among HFpEF patients\[^12\]. Furthermore, emerging data support the hypothesis that myocardial ischemia, secondary to CMD, is a key mechanism leading to pathological remodeling in HFpEF\[^4,13,14\]. Indeed, the impaired coronary microvascular function has been independently associated with features of HFpEF such as LV diastolic dysfunction and elevated highsensitivity cardiac troponin concentrations, leading to worse clinical outcomes and recurrent hospitalizations\[^4,13\]. Like CMD, other cardiovascular risk factors such as essential hypertension and DM can adversely impact cardiac remodeling\[^15\]. Previous studies demonstrated that CMD and HFpEF share similar risk factors, including age, obesity, hypertension, and DM\[^5,16\text{–}19\]. The current investigation builds upon these prior observations by directly comparing indices of LV morphology and myocardial perfusion in INOCA and HFpEF as compared to reference control participants.

A possible explanation for our findings is that participants in the HFpEF group are older, more obese, have a higher prevalence of DM, relatively more hypertensive, and therefore at greater risk of chronic myocardial microvascular ischemia evidenced by reduced perfusion. Thus, it is plausible that chronic exposure to myocardial ischemia may be linked to adverse remodeling.

Our study is limited by relatively small sample size and, therefore, limited in adjusting for confounding variables. Our study is also limited by the lack of a longitudinal design and the inability to decide the temporality of our findings. In addition, our focus on the INOCA and reference control groups of exclusive women limits the generalizability of these results to men. Finally, our recruitment of symptomatic INOCA participants limits generalizability to asymptomatic patients.
These data, taken together, support the hypothesis that CMD and other cardiovascular risk factors may play a pivotal role in driving heart failure progression in INOCA. However, future studies are needed to confirm the exact mechanistic link through longitudinal investigation of women with INOCA.

Financial support and sponsorship

This work was supported by contracts from the National Heart, Lung and Blood Institutes nos. R01 HL090957, the National Center for Advancing Translational Sciences Grant UL1TR000124, and grants the Edythe L. Broad and the Constance Austin Women’s Heart Research Fellowships, Cedars-Sinai Medical Center, Los Angeles, California, the Barbara Streisand Women’s Cardiovascular Research and Education Program, Cedars-Sinai Medical Center, Los Angeles, The Society for Women’s Health Research (SWHR), Washington, D.C., the Linda Joy Pollin Women’s Heart Health Program, the Erika Glazer Women’s Heart Health Project, and the Adelson Family Foundation, Cedars-Sinai Medical Center, Los Angeles, California. MD. MDN was supported by AHA16SDG27260115 and the Harry S. Moss Heart Trust. T. Jake Samuel was supported by AHA18PRE33960358 and the Harry S. Moss Heart Trust.

Conflicts of interest

Drs. Suppogu, Aldiwni, Suppogu, Shufelt, Cook-Wiens, Tamarappoo, Gill, Szczepaniak, Berman Thomson, Wei: Not applicable; Dr. Bairey Merz has disclosures from Sanofi, Abbott Diagnostics, and iRhythm. Dr. Pepine: Research Grant from Gilead Sciences, Inc, Pfizer, Park-Davis, Sanofi-Aventis, Fujisawa HealthCare Inc, Baxter, Brigham & Women’s Hospital, AstraZeneca, NIH/NHLBI, Amorcyte/Neostem, Cytori, InfraReDx, NHLBI/NCCR CTSA grant 1UL1RR029890, AHA. Consultant/Advisory Board: NIH Study Section of Cardiovascular Sciences Small Business Activities 2RG1 CVS-K-10, Lilly/Cleveland Clinic DSMB Member for a Phase 2 Efficacy and Safety Study of Ly2484595, Medtrigence, NHLBI Study Section for Progenitor Cell Biology Consortium, NHLBI DSMB Chair for Freedom Trial. Dr. Handberg receives research grants from Aastrom Biosciences, Amorcyte, Biocirdia, Brigham and Women’s Hospital, Capricor, Cytori Therapeutics, Department of Defense, Direct Flow Medical, Duke Clinical Research Institute, East Carolina University, Everyfit Inc., Medtronic, Merck & Co., Mesoblast, National Institutes of Health (NIH), NIH through University of Rochester, NIH through Brigham and Women’s Health, NIH through University of Texas, PCORI, and Sanofi Aventis; Research grant and educational grant from Gilead Sciences; Unrestricted educational grants for the Vascular Biology Working Group from Amgen, AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, Ionis, and Relypsa; and Consultant fees from Bristol-Myers Squibb Company.

Availability of data and materials

Data available upon request.

REFERENCES

1. AlBadri A, Lai K, Wei J, et al. Inflammatory biomarkers as predictors of heart failure in women without obstructive coronary artery disease: a report from the NHLBI-sponsored Women’s Ischemia Syndrome Evaluation (WISE). PLoS One 2017;12:e0177684. [PubMed: 28542263]
2. Merz CN, Pepine CJ, Walsh MN, Fleg JL. Ischemia and no obstructive coronary artery disease (INOCA): developing evidence-based therapies and research agenda for the next decade. Circulation 2017;135:1075–92. [PubMed: 28289007]
3. Bakir M, Nelson MD, Jones E, et al. Heart failure hospitalization in women with signs and symptoms of ischemia: a report from the women’s ischemia syndrome evaluation study. Int J Cardiol 2016;223:936–9. [PubMed: 27589041]
4. Taqueti VR, Solomon SD, Shah AM, et al. Coronary microvascular dysfunction and future risk of heart failure with preserved ejection fraction. Eur Heart J 2018;39:840–9. [PubMed: 29293969]
5. Thomson LE, Wei J, Agarwal M, et al. Cardiac magnetic resonance myocardial perfusion reserve index is reduced in women with coronary microvascular dysfunction. A national heart, lung, and blood institute-sponsored study from the women’s ischemia syndrome evaluation. Circ Cardiovasc Imaging 2015;8:e002481. [PubMed: 25801710]
6. Nelson MD, Sharif B, Shaw JL, et al. Myocardial tissue deformation is reduced in subjects with coronary microvascular dysfunction but not rescued by treatment with ranolazine. Clin Cardiol 2017;40:300–6. [PubMed: 28004395]

7. Nelson MD, Wei J, Bairey Merz CN. Coronary microvascular dysfunction and heart failure with preserved ejection fraction as female-pattern cardiovascular disease: the chicken or the egg? Eur Heart J 2018;39:850–2. [PubMed: 29346550]

8. Wei J, Bakir M, Darouian N, et al. Myocardial scar is prevalent and associated with subclinical myocardial dysfunction in women with suspected ischemia but no obstructive coronary artery disease: from the women’s ischemia syndrome evaluation-coronary vascular dysfunction study. Circulation 2018;137:874–6. [PubMed: 29459474]

9. Wei J, Mehta PK, Johnson BD, et al. Safety of coronary reactivity testing in women with no obstructive coronary artery disease: results from the NHLBI-sponsored WISE (Women’s Ischemia Syndrome Evaluation) study. JACC Cardiovasc Interv 2012;5:646–53. [PubMed: 22721660]

10. Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-st-elevation acute coronary syndromes: a report of the American college of cardiology/american heart association task force on practice guidelines. J Am Coll Cardiol 2014;64:e139–228. [PubMed: 22721660]

11. Ponikowski P, Voors AA, Anker SD, et al.; ESC Scientific Document Group. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016;37:2129–200. [PubMed: 27206819]

12. Shah SJ, Lam CSP, Svedlund S, et al. Prevalence and correlates of coronary microvascular dysfunction in heart failure with preserved ejection fraction: PROMIS-HFpEF. Eur Heart J 2018;39:3439–50. [PubMed: 30165580]

13. Elgendy IY, Pepine CJ. Heart failure with preserved ejection fraction: is ischemia due to coronary microvascular dysfunction a mechanistic factor? Am J Med 2019;132:692–7. [PubMed: 30684452]

14. Wei J, Nelson MD, Sharif B, Shufelt C, Bairey Merz CN. Why do we care about coronary microvascular dysfunction and heart failure with preserved ejection fraction: addressing knowledge gaps for evidence-based guidelines. Eur Heart J 2018;39:3451–3. [PubMed: 30165471]

15. Hoang K, Zhao Y, Gardin JM, et al. LV mass as a predictor of CVD events in older adults with and without metabolic syndrome and diabetes. JACC Cardiovasc Imaging 2015;8:1007–15. [PubMed: 26319502]

16. Shah SJ. Sedentary lifestyle and the risk for HFpEF: are “huff-puff health clubs” the answer? J Am Coll Cardiol 2017;69:1143–6. [PubMed: 28254176]

17. Agarwal M, Shufelt C, Mehta PK, et al. Cardiac risk factors and myocardial perfusion reserve in women with microvascular coronary dysfunction. Cardiovasc Diagn Ther 2013;3:146–52. [PubMed: 24282763]

18. Srivaratharajah K, Coutinho T, deKemp R, et al. Reduced myocardial flow in heart failure patients with preserved ejection fraction. Circ Heart Fail 2016;9:e002562. [PubMed: 27413034]

19. Wang L, Jerosch-Herold M, Jacobs DR Jr, Shahar E, Folsom AR. Coronary risk factors and myocardial perfusion in asymptomatic adults: the Multi-Ethnic Study of Atherosclerosis (MESA). J Am Coll Cardiol 2006;47:565–72. [PubMed: 16458137]
Figure 1.
Illustrating study participants selection criteria and the selected intervention for each group. CMRI: Cardiac magnetic resonance imaging; INOCA: ischemia with no obstructive coronary artery; CAD: coronary artery disease; HFpEF: heart failure with preserved ejection fraction; LVEF: left ventricular ejection fraction; STEMI: ST elevation myocardial infarction; MI: myocardial infarction; CTA: computed tomography angiography.
Figure 2.
Illustrating the total study participant enrolled and total study participants analyzed. INOCA: Ischemia with no obstructive coronary artery; HFpEF: heart failure with preserved ejection fraction; EF: ejection fraction.
## Table 1.

Baseline and age-adjusted characteristics and CMRI variables between reference controls, INOCA, and HFpEF

| Variable                     | Reference control (n = 8) | INOCA (n = 35) | HFpEF (n = 13) | P-value | Age-adjusted P-value |
|------------------------------|--------------------------|----------------|----------------|---------|----------------------|
| **Baseline characteristics** |                          |                |                |         |                      |
| Age                          | 48 (5)                   | 55 (10)        | 62 (12)        | 0.007   | -                    |
| BSA (m²)                     | 1.7 (0.1)                | 1.7 (0.2)      | 1.8 (0.2)      | 0.05    | 0.08                 |
| **Risk factors**             |                          |                |                |         |                      |
| Hypertension                 | 0                        | 12 (40.0%)     | 9 (75.0%)      | 0.003   | -                    |
| Diabetes mellitus            | 0                        | 2 (6.5%)       | 4 (30.8%)      | 0.05    | -                    |
| Former smoker                | 0                        | 10 (32.3%)     | 6 (46.2%)      | 0.5     | -                    |
| Current smoker               | 0                        | 2 (6.5%)       | 1 (7.7%)       | 1       | -                    |
| Dyslipidemia                 | 1 (12.5%)                | 2 (8.3%)       | 1 (10.0%)      | 1       | -                    |
| Family history of CAD        | 2 (25%)                  | 22 (71%)       | 6 (46.2%)      | 0.04    | -                    |
| **Medications**              |                          |                |                |         |                      |
| Beta blockers                | 0                        | 6 (22.2%)      | 8 (80%)        | 0.002   | -                    |
| Calcium channel blockers     | 0                        | 13 (48.1%)     | 4 (50%)        | 1       | -                    |
| Nitrates                     | 0                        | 12 (48%)       | 2 (20%)        | 0.25    | -                    |
| Aspirin                      | 0                        | 23 (82.1%)     | 7 (63.6%)      | 0.24    | -                    |
| ACEIs                        | 0                        | 10 (35.7%)     | 2 (20%)        | 0.45    | -                    |
| ARBs                         | 0 (0.0%)                 | 1 (3.8%)       | 0              | 1       | -                    |
| Statins                      | 0                        | 19 (67.9%)     | 6 (54.5%)      | 0.48    | -                    |
| SAQ-7 questionnaire          | -                        | 52.1 (19.5)    | 70.2 (30)      | 0.02    | 0.09                 |
| KCCQ clinical summary        | -                        | 70.1 (18.8)    | 62.9 (22.3)    | 0.28    | 0.11                 |
| KCCQ overall summary         | -                        | 62.7 (22.7)    | 62.6 (24.1)    | 0.99    | 0.49                 |
| KCCQ physical limitation     | -                        | 73.6 (19.9)    | 68.5 (27.9)    | 0.5     | 0.27                 |
| KCCQ quality of life         | -                        | 48.9 (29.4)    | 59.0 (33.1)    | 0.33    | 0.7                  |
| KCCQ symptom burden          | -                        | 63.6 (22.9)    | 58.3 (27)      | 0.51    | 0.25                 |
| KCCQ self-efficacy           | -                        | 67.9 (29.8)    | 80.8 (18.1)    | 0.16    | 0.26                 |
| KCCQ symptom frequency       | -                        | 69.4 (20.8)    | 60.9 (24.6)    | 0.25    | 0.07                 |
| KCCQ social limitation       | -                        | 61.6 (29.9)    | 66.0 (31.9)    | 0.68    | 0.85                 |
| KCCQ symptom stability       | -                        | 50.8 (24.1)    | 44.2 (11)      | 0.35    | 0.29                 |
| Variable                  | Reference control ($n=8$) | INOCA ($n=35$) | HFpEF ($n=13$) | $P$-value | Age-adjusted $P$-value |
|--------------------------|--------------------------|----------------|----------------|-----------|------------------------|
| KCCQ total symptom score | -                        | 66.5 (21.1)    | 59.6 (23)      | 0.34      | 0.12                   |
| **CMRI variables**       |                          |                |                |           |                        |
| LV EF (%)                | 66.6 (4.3)               | 61.8 (5.5)     | 62.0 (5)       | 0.07      | **0.02**               |
| LVEDV (mL)               | 105.7 (10.6)             | 115.7 (16.7)   | 113.0 (26.8)   | 0.4       | 0.35                   |
| LVEDV index (mL/m$^2$)   | 63.5 (7.0)               | 68.5 (8.5)     | 62.9 (16.8)    | 0.21      | 0.24                   |
| LVESV (mL)               | 35.4 (6.1)               | 44.6 (11.2)    | 43.7 (15.1)    | 0.14      | 0.07                   |
| LVESV index (mL/m$^2$)   | 21.3 (4.0)               | 26.3 (5.7)     | 24.3 (8.7)     | 0.12      | 0.07                   |
| LV stroke (mL)           | 70.3 (7.9)               | 71.1 (9.7)     | 69.3 (13.6)    | 0.87      | 0.84                   |
| LV mass (g)              | 67.8 (7.2)               | 76 (10.8)      | 81.9 (23.1)    | 0.1       | 0.31                   |
| LV mass to volume        | 0.6 (0.1)                | 0.7 (0.1)      | 0.7 (0.2)      | 0.09      | 0.4                    |
| LV mass index (g/m$^2$)  | 40.6 (3.7)               | 44.9 (4.9)     | 45.1 (12)      | 0.28      | 0.47                   |
| **MPRI**                 |                          |                |                |           |                        |
| MPRI transmural          | 1.9 (0.3)                | 1.8 (0.3)      | 1.5 (0.3)      | **0.03**  | 0.13                   |
| MPRI epicardial          | 2.0 (0.3)                | 1.9 (0.3)      | 1.6 (0.3)      | **0.01**  | **0.03**               |
| MPRI subendocardial      | 1.7 (0.3)                | 1.6 (0.3)      | 1.4 (0.3)      | 0.11      | 0.34                   |
| **CFT variables**        |                          |                |                |           |                        |
| CFR                      |                          |                |                |           |                        |
| Change in coronary artery diameter (%) | -1 ± 15.9 |                |                |           |                        |
| Nitroglycerin response (%) | 22.3 ± 32.7          |                |                |           |                        |
| CBF (%)                  |                          |                |                |           | 48.3 ± 56              |

BSA: Body surface area; MPRI: myocardial perfusion reserve index; SAQ: Seattle angina questionnaire; LVESV: left ventricular end-systolic volume; LVEDV: left ventricular end-diastolic volume; CFT: coronary function test; CFR: coronary flow reserve.